TAK06100

omontys  

The anemia drug peginesatide (Omontys, Affymax and Takeda Pharmaceuticals) has been voluntarily recalled by the manufacturers after reports of anaphylaxis leading to 3 deaths, the US Food and Drug Administration (FDA) announced today.

The FDA approved peginesatide in March 2012 for treating anemia caused by chronic kidney disease in adult patients receiving dialysis. The injectable drug is packaged in 10-mg and 20-mg multidose vials.

According to postmarketing reports from the manufacturers, roughly 0.2% of the 25,000 patients receiving the drug since its approval have experienced hypersensitivity reactions. One third of these cases have involved 19 cases of anaphylaxis and other serious adverse events that required prompt medical intervention and sometimes hospitalization. The 3 fatal reactions represent 0.02% of patients receiving peginesatide.

The serious hypersensitivity reactions reported to the FDA have occurred within 30 minutes of the first dose of intravenous administration, but not after any subsequent doses or after the completion of a dialysis session.

There have been no reports of hypersensitivity reaction when the drug is injected subcutaneously, but the "subcutaneous numbers are limited," said Affymax Chief Executive Officer John Orwin in a telebriefing today.

Orwin said that his company and Takeda Pharmaceuticals will assess which types of patient are at the highest risk for hypersensitivity reaction. Right now they do not know of any patient-specific characteristics associated with the hypersensitivity cases.

"This is a surprising and unfortunate turn of events," said Orwin.

Clinicians and dialysis centers should immediately discontinue administering peginesatide and return the product to Takeda Pharmaceuticals, the FDA said.

More information about the recall is available on the FDA Web site.

To report problems with peginesatide injection, contact MedWatch, the FDA's safety information and adverse event reporting program, by telephone at 1-800-FDA-1088; by fax at 1-800-FDA-0178; online at https://www.accessdata.fda.gov/scripts/medwatch/medwatch-online.htm; with postage-paid FDA form 3500, available at http://www.fda.gov/MedWatch/getforms.htm; or by mail to MedWatch, 5600 Fishers Lane, Rockville, Maryland 20852-9787.

arrow
arrow

    快樂小藥師 發表在 痞客邦 留言(0) 人氣()